QQ客服 官方微博 反馈留言

浏览/检索结果: 共10条，第1-10条 帮助 已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Prognostic Factors in Early-stage NSCLC: Analysis of the Placebo Group in the MAGRIT Study 期刊论文 ANTICANCER RESEARCH, 2019, 卷号: 39, 期号: 3 作者:  Cho, Byoung Chul;  De Pas, Tommaso;  Kalofonos, Haralabos;  Wang, Qun;  Ramlaus, Rodryg 收藏  |  浏览/下载：5/0  |  提交时间：2019/12/05 Non-small cell lung cancer  MAGE-A3 cancer immunotherapeutic  prognostic factors  placebo  overall survival   First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression 期刊论文 2019, 卷号: 145, 期号: 6, 页码: 1569-1579 作者:  Schuler, Martin;  Tan, Eng-Huat;  O'Byrne, Kenneth;  Zhang, Li;  Boyer, Michael 收藏  |  浏览/下载：20/0  |  提交时间：2020/01/03 Afatinib  EGFR  NSCLC  Dose adjustment  Time-to-treatment failure   First-Line Afatinib versus Gefitinib in EGFRm plus Advanced NSCLC: Updated Overall Survival Analysis of LUX-Lung 7 期刊论文 2017, 卷号: 12, 期号: 1, 页码: S335-S336 作者:  Park, Keunchil;  Tan, Eng Huat;  Zhang, Li;  Hirsh, Vera;  O'Byrne, Ken 收藏  |  浏览/下载：7/0  |  提交时间：2020/01/03 afatinib  gefitinib  NSCLC  EGFR   Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial 期刊论文 2016, 卷号: 17, 期号: 5, 页码: 577-589 作者:  Park, Keunchil;  Tan, Eng-Huat;  O'Byrne, Ken;  Zhang, Li;  Boyer, Michael 收藏  |  浏览/下载：4/0  |  提交时间：2020/01/04 First-line afatinib (A) vs gefitinib (G) for patients (pts) with EGFR mutation positive (EGFRm plus ) NSCLC (LUX-Lung 7): Patient-reported outcomes (PROs) and impact of dose modifications on efficacy and adverse events (AEs). 期刊论文 2016, 卷号: 34, 期号: 15 作者:  Hirsh, Vera;  Yang, James Chih-Hsin;  Tan, Eng-Huat;  O'Byrne, Ken;  Zhang, Li 收藏  |  浏览/下载：6/0  |  提交时间：2020/01/04 First-line afatinib (A) vs gefitinib (G) for patients (pts) with EGFR mutation positive (EGFRm plus ) NSCLC (LUX-Lung 7): Patient-reported outcomes (PROs) and impact of dose modifications on efficacy and adverse events (AEs). 会议论文 JOURNAL OF CLINICAL ONCOLOGY, 2016-05-20 作者:  Hirsh, Vera;  Yang, James Chih-Hsin;  Tan, Eng-Huat;  O'Byrne, Ken;  Zhang, Li 收藏  |  浏览/下载：7/0  |  提交时间：2020/01/04 EGFR Mutation Testing Practices within the Asia Pacific Region Results of a Multicenter Diagnostic Survey 期刊论文 JOURNAL OF THORACIC ONCOLOGY, 2015, 卷号: 10, 期号: 3 作者:  Yatabe, Yasushi;  Kerr, Keith M.;  Utomo, Ahmad;  Rajadurai, Pathmanathan;  Van Khanh Tran 收藏  |  浏览/下载：4/0  |  提交时间：2019/12/19 EGFR mutation  Non-small-cell lung cancer  Testing  Survey  Multicenter   EGFR mutation testing practices within the Asia Pacific region: results of a multicenter diagnostic survey 期刊论文 2015, 卷号: 10, 期号: 3, 页码: 438-45 作者:  Yatabe Yasushi;  Kerr Keith M;  Utomo Ahmad;  Rajadurai Pathmanathan;  Tran Van Khanh 收藏  |  浏览/下载：5/0  |  提交时间：2020/01/04 SUBSET ANALYSES OF EAST ASIAN PATIENTS ENROLLED IN THE MISSION PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF SORAFENIB MONOTHERAPY IN PATIENTS WITH ADVANCED RELAPSED/REFRACTORY NSCLC OF PREDOMINANTLY NON-SQUAMOUS HISTOLOGY WHO 期刊论文 2012, 卷号: 7, 期号: 11, 页码: S458-S458 作者:  Mok, Tony S. K.;  Wu, Yi-long;  Zhou, Caicun;  Sun, Yan;  Zhang, Li 收藏  |  浏览/下载：2/0  |  提交时间：2020/01/13 NSCLC  sorafenib  MISSION Trial  East Asian   Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial 期刊论文 2012, 卷号: 13, 期号: 5, 页码: 528-538 作者:  Miller, Vincent A.;  Hirsh, Vera;  Cadranel, Jacques;  Chen, Yuh-Min;  Park, Keunchil 收藏  |  浏览/下载：2/0  |  提交时间：2020/01/13